Clinical Trial Update: Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Results from a Phase 2 trial evaluating ibrutinib in relapsed or refractory classical Hodgkin lymphoma have been completed and posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma

Drugs mentioned

• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Classical Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2025-02-17